CTOs on the Move

Landos Biopharma

www.landosbiopharma.com

 
Landos pursues safer, more effective first-in-class oral therapeutics for autoimmune disorders at an accelerated rate.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Landos Biopharma raised $10M on 09/21/2017

Similar Companies

Dey Pharmaceuticals

Dey Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Beacon Orthopaedics & Sports Medicine

Beacon Orthopaedics has 40 renowned orthopedic surgeons providing Cincinnati, Dayton, NKY and Indiana specialized sports medicine and orthopedic care.

Mobile Physician Services

Mobile Physician Services is a practice of doctors and nurse practitioners who make house calls to homebound patients. We specialize in the treatment of patients with complex medical needs. MPS is one of the only house call practices in the United Sta...

Teva Canada

Teva Canada is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.